On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine under review while we revisit our assumptions, and because DOV Pharmaceutical DOVP is entitled to a royalty on any indiplon ...
Our Ultimate Stock-Pickers Index continues to beat the market even as relatively few of our top managers are outperforming the S&P 500.
Widening investment-grade credit spreads and rising interest rates lead to losses.
We like 3-D printer firms' growth fundamentals, but current valuations limit long-term investor returns.
Industrial activity remains slow and steady, giving companies a chance to navigate the environment.
A number of technical factors in the municipal bond market have magnified the selling pressure.